COST-EFFECTIVENESS OF TP53 AND IGHV BIOMARKER TESTING PRIOR TO FIRST-LINE TREATMENT WITH NOVEL AGENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA

被引：0
|
作者：
Vu, M. [1 ]
Degeling, K. [1 ]
Thompson, E. [2 ]
Blombery, P. [2 ]
Westerman, D. A. [2 ]
IJzerman, M. [1 ]
机构：
[1] Univ Melbourne, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE141
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [1] Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia
    Le Bris, Yannick
    Struski, Stephanie
    Guieze, Romain
    Rouvellat, Caroline
    Prade, Nais
    Troussard, Xavier
    Tournilhac, Olivier
    Bene, Marie C.
    Delabesse, Eric
    Ysebaert, Loic
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 664 - 670
  • [2] Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran
    Fariman, Soroush
    Nasab, Fatemeh Momeni
    Faraji, Hoda
    Afzali, Monireh
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 38 : 93 - 100
  • [3] THE COST-EFFECTIVENESS OF BENDAMUSTINE VERSUS FLUDARABINE FOR THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN MEXICO
    Bertwistle, D.
    Munakata, J.
    Wehler, E.
    Leyva, V
    Valencia, A.
    Hernandez, A.
    de la Torre, L.
    Gonzalez, L.
    VALUE IN HEALTH, 2013, 16 (07) : A409 - A409
  • [4] Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia
    Alrawashdh, Neda
    McBride, Ali
    Erstad, Brian
    Sweasy, Joann
    Persky, Daniel O.
    Abraham, Ivo
    VALUE IN HEALTH, 2022, 25 (10) : 1685 - 1695
  • [5] COST-EFFECTIVENESS OF OFATUMUMAB PLUS CHLORAMBUCIL IN FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED KINGDOM
    Pearson, I., V
    Hawe, E.
    Zuluaga, S.
    Wolowacz, S.
    Haiderali, A.
    VALUE IN HEALTH, 2015, 18 (07) : A455 - A455
  • [6] Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia
    Harkins, R. Andrew
    Patel, Sharvil P.
    Flowers, Christopher R.
    CANCER JOURNAL, 2019, 25 (06): : 418 - 427
  • [7] Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia
    Patel, Kishan K.
    Isufi, Iris
    Kothari, Shalin
    Davidoff, Amy J.
    Gross, Cary P.
    Huntington, Scott F.
    BLOOD, 2020, 136 (17) : 1946 - 1955
  • [8] Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia
    Mueller, Dirk
    Fischer, Kirsten
    Kaiser, Peter
    Eichhorst, Barbara
    Walshe, Ronald
    Reiser, Marcel
    Kellermann, Lenka
    Borsi, Lisa
    Civello, Daniele
    Mensch, Alexander
    Bahlo, Jasmin
    Hallek, Michael
    Stock, Stephanie
    Fingerle-Rowson, Guenter
    LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1130 - 1139
  • [9] Cost-effectiveness of imatinib (GLEEVEC) as first-line treatment in chronic myeloid leukemia (CML)
    El Quagari, K
    Talbot, W
    Baladi, JF
    VALUE IN HEALTH, 2004, 7 (06) : 669 - 669
  • [10] Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation
    Bracher, Susanne
    Fuhrmann, Irene
    Jeromin, Sabine
    Nadarajah, Niroshan
    Kern, Wolfgang
    Haferlach, Torsten
    Haferlach, Claudia
    Stengel, Anna
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (12) : 12247 - 12252
12345